DEA Marijuana Policy  Reform - Matthew Strait you're Fired - Highlighted in Heated Oversight Congressional Hearing
Press Release

DEA Marijuana Policy Reform - Matthew Strait you're Fired - Highlighted in Heated Oversight Congressional Hearing

"This is insanity," declares Duane Boise, CEO of MMJ International Holdings, echoing the sentiments of lawmakers and researchers alike. The 2020 House Oversight Committee hearing, and ongoing developments, have laid bare the Drug Enforcement Administration's (DEA) persistent obstruction of legitimate cannabis research, a battle MMJ has been fighting since their 2018 application. Despite bipartisan congressional outrage, as highlighted by Representative Earl "Buddy" Carter's scathing critique of the DEA's "epitome of ineptitude," and the agency's own hollow defenses, the DEA, represented by figures like Matthew Strait and Thomas Prevoznik, continues to delay and deny, hindering vital medical advancements. Boise's lawsuit against the DEA underscores the urgent need for reform, as the agency's actions not only impede scientific progress but also deny patients access to potentially life-changing treatments, a situation that demands immediate structural changes in federal cannabis policy.

Read More
DEA's Marijuana Policy Mission at Odds with Its Actions - MMJ's DEA Lawsuit Positioned to Win
Press Release

DEA's Marijuana Policy Mission at Odds with Its Actions - MMJ's DEA Lawsuit Positioned to Win

AS WRITTEN DEA MISSION:

Prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs. 

Duane Boise MMJ's CEO mentioned that “Thomas Prevoznik DEA Diversion DEPUTY ADMINISTRATOR 's adamant unwillingness to utilize his critical thinking faculties or examine his colossal stubbornness is captive to his unwarranted certainties which are holding him objectivity hostage”. The DEA's continued obstruction risks not only legal defeat but also reputational harm as patients await life-saving therapies.

Read More